CancerLinQ and NCCN Collaborating to Provide Evidence-Based, Decision-Making Resources to Physicians

New Collaboration Will Grant CancerLinQ® Subscribers Streamlined Access to the NCCN Compendium®
For immediate release
May 31, 2017


Kate Crawford

ALEXANDRIA, VA.—CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO®), and the National Comprehensive Cancer Network® (NCCN®) announced today a collaboration to provide a link to the NCCN website for easy access to the NCCN Drugs & Biologics Compendium (NCCN Compendium®) within CancerLinQ®. This resource will support CancerLinQ® physicians and provides evidence-based guidance regarding the appropriate use of drugs and biologics in patients with cancer.

“CancerLinQ® exists in service to our members to improve quality,” said CancerLinQ LLC Chief Executive Officer Kevin Fitzpatrick. “As we continue to convene collaborators across the oncology community, we encourage efforts that enable resources to be more easily accessible for providers to make informed and timely decisions in the delivery of care to their patients. This collaboration is just one more positive step in that direction.”

With this collaboration, CancerLinQ® subscribers will now have access to a link that will bring them directly to the NCCN Compendium®, where they can subscribe for a fee. NCCN is able to make available its resources to the growing CancerLinQ network, which includes thousands of oncologists treating millions of patients from a variety of practice types and institutions across the United States. The collaboration represents just one of the ways in which CancerLinQ LLC is convening the oncology community by bringing resources together to enable the work of those who care for patients in whatever care setting they may be located.

“We are pleased to collaborate with ASCO and CancerLinQ® to support clinician access to evidence-based resources through technology at the point of care,” said NCCN Chief Executive Officer Robert W. Carlson, MD. “Based directly on the NCCN Guidelines, the Compendium will benefit CancerLinQ® users by providing authoritative, scientifically derived information designed to support decision-making about the appropriate use of drugs and biologics in patients with cancer.”

The NCCN Compendium contains recommendations for the appropriate use of drugs and biologics to support decision-making for patients with cancer. The recommendations are derived directly from relevant NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) along with their clinical context, route of administration, recommended use, and NCCN category of evidence. In addition to NCCN Guidelines-specific indication and use, NCCN adds relevant information, such as pharmacologic class, relevant classification codes, and U.S. Food and Drug Administration indication, to the searchable database. All information is reviewed by members of the relevant NCCN Guidelines® panel before publication.

The collaboration with NCCN is one of many that CancerLinQ LLC is pursuing with a coalition of partners and thought leaders, including government agencies, medical specialty societies and life sciences organizations to receive expert guidance and gain insights that can improve quality and efficiency of the cancer care delivery system. Recent partnerships include those with: the American Academy of Physician AssistantsAmerican Society of Radiation OncologyCancer Informatics for Cancer CentersCollege of American PathologistsHematology/Oncology Pharmacy AssociationOncology Nursing Society, and Society of Gynecologic Oncology.

The CancerLinQ® platform is a big data initiative focused on cancer patient medical information, aimed at improving the quality of patient care and outcomes. It is the only major cancer data initiative being developed and led by physicians. When complete, CancerLinQ will unlock real-world patient care data from millions of electronic health records and securely process and analyze the data to provide immediate quality feedback and clinical decision support to providers. Doctors will receive personalized insights on a scope that was previously unattainable, and patients will benefit by having access to high quality care based on up-to-date insights and findings.

CancerLinQ is supported in part through the Conquer Cancer Foundation, whose generous donors have helped make the system possible. Major supporters include Amgen; Astellas; AstraZeneca; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cancer Treatment Centers of America®; Chan Soon-Shiong Family Foundation; Genentech BioOncology™; HELSINN; Janssen Oncology; Lilly; Raj Mantena, RPh; Novartis Oncology; Pfizer Oncology; Thomas G. Roberts, Jr., MD, and Susan M. DaSilva; and Susan G. Komen®.

CancerLinQ is a project of CancerLinQ LLC. For more information, please visit

About ASCO: 

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents more than 40,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, and YouTube.